Form 4: Foghorn Therapeutics Inc. Executive Anna Rivkin Acquires Stock Options
SEC Form 4 Filing
Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc., reports the acquisition of stock options.
Summary
- Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc. (FHTX), filed a Form 4.
- The filing reports the acquisition of stock options.
- Rivkin acquired options to purchase 50,000 shares of common stock on January 22, 2025, at an exercise price of $4.37.
- The options vest as to 25% on January 22, 2026, and then at a rate of 6.25% per quarter thereafter.
- Following the transaction, Rivkin directly owns options for 50,000 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a company executive's acquisition of stock options, a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The stock option grant may incentivize the executive to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/22/2025 | Date of transaction: Anna Rivkin acquired stock options. |
| 01/22/2026 | 25% of the acquired stock options vest. |
| 01/21/2035 | Expiration date of the stock options. |
| 01/24/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.